Photocure ASA
OSE:PHO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Photocure ASA
Other Current Liabilities
Photocure ASA
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
Other Current Liabilities
kr76m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
8%
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Other Current Liabilities
kr48.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
3%
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Other Current Liabilities
kr53.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
15%
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Other Current Liabilities
-kr160k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncoinvent ASA
OSE:ONCIN
|
Other Current Liabilities
kr14m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Other Current Liabilities?
Other Current Liabilities
76m
NOK
Based on the financial report for Dec 31, 2025, Photocure ASA's Other Current Liabilities amounts to 76m NOK.
What is Photocure ASA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
8%
Over the last year, the Other Current Liabilities growth was 11%. The average annual Other Current Liabilities growth rates for Photocure ASA have been 11% over the past three years , -1% over the past five years , and 8% over the past ten years .
